# Redalpine Closes Oversubscribed $250M RAC VIII Fund for European Seed and Series A Startups > Redalpine closes its oversubscribed $250M RAC VIII fund to lead seed and Series A rounds in about 20 European startups, backed by Aviva Investors and KfW. - **Author:** Swati k jagtap - **Published:** 2026-11-11 - **Updated:** 2026-11-11 - **Category:** Funding - **Editorial type:** news - **Topics:** venture-capital-fund, seed-funding, series-a, deeptech, ai, robotics, european-vc - **Canonical URL:** https://www.todaysstartupnews.com/funding/redalpine-250-million-rac-viii-fund-seed-series-a-europe ## Key takeaways - Redalpine has closed RAC VIII, its eighth early-stage fund, at an oversubscribed $250 million - The fund is 25 percent larger than RAC VII, which closed at $200 million in 2024, and takes assets under management above $1.4 billion - It will invest mainly at seed and Series A with initial tickets of $1 million to $15 million in about 20 European startups - Limited partners include Aviva Investors, Flexstone Partners and KfW, and focus areas include robotics and AI for drug discovery European venture capital firm Redalpine has closed its eighth early-stage fund, Redalpine Capital VIII (RAC VIII), at $250 million. The firm announced the final close on November 10, 2026, and describes the fund as oversubscribed. RAC VIII is the largest early-stage fund in Redalpine's history. It is 25 percent larger than the previous vehicle, RAC VII, which closed at $200 million in August 2024. With the new fund, the firm reports assets under management above $1.4 billion. The fund will invest mainly at seed and Series A stage, with initial investments of between $1 million and $15 million. Redalpine says it will aim to lead or co-lead the rounds it joins. The firm plans to back between 15 and 20 startups across Europe. Trending Topics reports that these will be selected from more than 5,000 companies the firm reviews each year. Areas of focus include robotics and artificial intelligence for drug discovery. Half of Redalpine's investment team are scientists, according to the firm. RAC VIII has drawn commitments from both long-standing and new investors. Named limited partners include Aviva Investors, the asset management arm of the UK insurer Aviva, Flexstone Partners and German development bank KfW. Trending Topics reports that the fundraising was completed in less than a year. Sebastian Becker, general partner at Redalpine, said artificial intelligence is levelling the playing field more than before, and that the advantage now lies with those who best understand the underlying science and the hardest problems. In his view, that has always been a European strength. He added that the firm is seeing a new generation of ambitious founders who want to build and scale leading technology companies in Europe and establish the continent as a global technology power. Redalpine says startups backed by RAC VII, whose portfolio is close to 50 percent UK-based, have since raised more than $1.1 billion in combined funding. The firm was founded in Zurich in 2006 and invests in technology and science startups across Europe. Besides Zurich, it has offices in Berlin and London and a presence in Silicon Valley. Its previous investments include Mistral, N26, Basecamp Research and Proxima Fusion. According to coverage of the fund close, RAC VIII has already made its first investments. These include Enact Intelligence, a Swiss robotics startup that raised a $30 million pre-seed round in October 2026, Helical, a London-based company building AI tools for drug discovery, and Arlequin AI, a Paris company developing topological neural networks that raised a EUR 28 million Series A in September 2026 alongside OTB Ventures. The fund has room for further investments over the coming years within its range of about 20 companies. RAC VII was announced on August 27, 2024, from Zurich, at $200 million, which at the time made it Redalpine's largest fund. The firm opened a London office alongside that close. Trade coverage at the time described the fund as oversubscribed and said it would back 15 to 20 early-stage European companies in areas including AI, energy transition and health. Redalpine was founded by software entrepreneur Peter Niederhauser and molecular biologist Michael Sidler, according to the firm's materials. It says it has backed more than 100 companies over two decades and has developed a platform that supports founders from seed to later stages, including an evergreen vehicle called the Summit Fund. The 2026 announcement coincides with the firm's twentieth anniversary. RAC VIII closed at $250 million and was oversubscribed. It targets seed and Series A rounds with initial tickets from $1 million to $15 million, aims to lead or co-lead, and plans investments in roughly 15 to 20 European startups. Limited partners named in the announcement are Aviva Investors, Flexstone Partners and KfW. Redalpine's offices are in Zurich, Berlin and London, with a presence in Silicon Valley, and its stated focus areas include robotics and AI for drug discovery. The full details of the fund close were published by Redalpine through a newswire release on November 10, 2026.